CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on understanding and reducing the development of anti-drug antibodies in patients with hemophilia A, particularly those who develop inhibitors against therapeutic factor VIII. It aims to train researchers in immunology and hemostasis while fostering innovative therapeutic approaches through practic…
The development of anti-drug antibodies is the major complication of treatment with biotherapeutics.
This is particularly trueof patients with haemophilia A (HA) who develop neutralizing antibodies to therapeutic factor VIII (FVIII) followingreplacement therapy with exogenous pro-coagulant FVIII.
The onset of neutralizing antibodies to FVIII, referred to as FVIIIinhibitors, represents a major societal concern owing to the enormous cost associated to the clinical management ofinhibitor-positive p…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Stichting Sanquin Bloedvoorziening
Netherlands, Amsterdam
Type: Research institute
Activity type: Research Organisations
SME: No
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Frankfurt Am Main
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Bonn
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
